Market Cap (In CAD)
222.71 Million
Revenue (In CAD)
21.25 Million
Net Income (In CAD)
-16.04 Million
Avg. Volume
1125.00
- Currency
- CAD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.65-15.43
- PE
- -
- EPS
- -
- Beta Value
- 0.267
- ISIN
- CA31447P1009
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Rostislav Raykov
- Employee Count
- -
- Website
- https://www.fennecpharma.com
- Ipo Date
- 2001-06-12
- Details
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
More Stocks
-
ADVLIFEAdvance Lifestyles Limited
ADVLIFE
-
180640Hanjin Kal
180640
-
CBIA
-
DBGI
-
UNISTRMUUnistar Multimedia Limited
UNISTRMU
-
FUGI
-
NINE
-
KAYNES